Nature Biotechnology
15, 1318 - 1319 (1997)
doi:10.1038/nbt1297-1318
Drug Development: The role of innovation in drug developmentJürgen Drews1
& Stefan Ryser1
1Jürgen Drews is president of global research and Stefan Ryser is chief of international research staff, Hoffmann-La Roche, CH-4002 Basel, Switzerland (stefan.ryser@roche.com).
REFERENCES
- Human disease—From genetic causes to biochemical effects. Proceedings of the Roche Symposium "The Genetic Basis of Human Disease", October 2−3, 1996, Basel. Drews, J. and Ryser, S. (eds.) Ex Libris Roche 9. Blackwell Science, Berlin.
- Lifton, R. Human disease—From genetic causes to biochemical effects. Proceedings of the Roche Symposium "The Genetic Basis of Human Disease", October 2−3, 1996, Basel. Drews, J. and Ryser, S. (eds.) Ex Libris Roche 9. Blackwell Science, Berlin.
- Weber, W. 1997. pp. 10−11 in Pharmacogenetics. Oxford Univ. Press, New York and Oxford.
- Ohsako, S. and Deguchi, T. 1990. J. Biol. Chem. 265: 4630−4634. | PubMed | ISI | ChemPort |
- Weber, W. 1997. pp. 12−13 in Pharmacogenetics. Oxford Univ. Press, New York and Oxford.
- Mossinghoff, G.J. 1995. Drug Info. J. 29: 1077−1090.
- Drews, J. and Ryser, S. 1997. Drug Discovery Today 2: 365−372. | Article | ISI |
- It is obvious that these constraints are entirely dependent on a set of financial assumptions relating to costs, sales and discount rates for R&D expenditures. If these assumptions are modified, if for instance the discount rates after launch are lowered from 14% to 8% or if only out of pocket expenses are taken into account and opportunity costs altogether neglected, the picture brightens considerably. Eventually, such changes may have to be made.
|
